How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

Key Points

• To explore the relationship between pulmonary function and health-related quality of life in NSCLC patients during treatment.
• Assess pulmonary function in stage III NSCLC patients receiving chemoradiotherapy and durvalumab.
• Monitor health-related quality of life using standardized measures during treatment.
• Analyze associations between lung function and quality of life metrics.
• Health-related quality of life remained stable during treatment.
• Impaired lung function was linked to lower health-related quality of life scores.
• Further research is required to investigate subgroup effects.

Abstract